GTP 14564
1 Image
Description: Class III receptor tyrosine kinase (RTK) inhibitor
Chemical Name: 3-Phenyl-1H-benzofuro[3,2-c]pyrazole
Purity: ≥99%
Biological Activity
GTP 14564 is a potent, selective inhibitor of class III receptor tyrosine kinases (IC50 values are 0.3 μM for c-Fms, c-Kit, FLT3 and ITD-FLT3 and 1 μM for PDGFRβ). Displays no activity against ERK1, ERK2, EGFR, MEK1, HER2, Src, Abl, PKC, PKA and Akt (IC50 > 10 μM). Inhibits FL-dependent proliferation in BaF/ITD-FLT3 cells more potently than BaF/wt-FLT3 cells; anti-leukemic.Technical Data
M.Wt:
234.26
Formula:
C15H10N2O
Solubility:
Soluble to 100 mM in DMSO and to 25 mM in ethanol
Purity:
≥99%
Storage:
Store at +4°C
CAS No:
34823-86-4
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Background References
-
Selective cytotoxic mechanism of GTP-14564, a novel tyrosine kinase inhibitor in leukemia cells expressing a constitutively active Fms-like tyrosine kinase 3 (FLT3).
Murata et al.
J.Biol.Chem., 2003;278:32892 -
Human leukemias with mutated FLT3 kinase are synergistically sensitive to FLT3 and Hsp90 inhibitors: the key role of the STAT5 signal transduction pathway.
Yao et al.
Leukemia, 2005;19:1605
Product Datasheets
Reconstitution Calculator
Molarity Calculator
Reconstitution Calculator
Molarity Calculator
FAQs
No product specific FAQs exist for this product, however you may
View all Small Molecule FAQsReviews for GTP 14564
There are currently no reviews for this product. Be the first to review GTP 14564 and earn rewards!
Have you used GTP 14564?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris Bioscience is the leading supplier of novel and exclusive
tools for
life science research with over 30 years' experience in the
industry.
Tocris is a Bio-Techne brand.
